UPDATE 1-Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval

UPDATE 1-Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval


May 22 The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals Inc and Sanofi SA's biotech drug for adults with moderate to severe rheumatoid arthritis, the two companies said on Monday. The drug, sarilumab, which will be sold under the brand name Kevzara, will carry a list price of $39,000 per year for the 200 milligram and 150 mg doses, which the companies said was about 30 percent lower than the list price for the two most widely used rival medicines in the highly competitive space.



from Biotech News